

Media Release

Hyphens Pharma completes acquisition of Ardence Pharma Sdn Bhd

- With the acquisition of the 36,000 Tranche 3 Sale Shares, representing an 18% shareholding, Hyphens Pharma now owns a 100% shareholding interest in Ardence Pharma, making a wholly-owned subsidiary of the Group

Singapore, 17 April 2026 – Hyphens Pharma International Limited (“**Hyphens Pharma**”, “**凯帆药剂国际有限公司**”, or the “**Company**”, and together with its subsidiaries, the “**Group**”), today announced the completion of acquisition of 36,000 shares of Ardence Pharma Sdn Bhd (“**Ardence Pharma**”), representing the remaining 18% shareholding in Ardence Pharma (“**Tranche 3 Sale Shares**”), for a total consideration of RM15,945,133 (S\$5,177,000¹), subject to adjustments as prescribed under the Sales and Purchase Agreements (the “**Completion**”). The consideration is to be settled utilising the Group’s internal resources, and with the Completion, Ardence Pharma is now a wholly-owned subsidiary of the Group.

Growing the Medical Aesthetics business

Ardence Pharma is a boutique pharmaceutical company specialising in aesthetic medicine that provides cutting-edge, innovative, and clinically proven aesthetic products to physicians and consumers. Backed by its portfolio of ethical products, medical devices, and skincare ranges, Ardence Pharma is a key part of the Group’s Medical Aesthetics business. The Group is leveraging the “Ardence” brand to drive the development of its Medical Aesthetics business and expansion into the region. The Medical Aesthetics business current regional footprint includes the Singapore and Malaysia markets, where the Group has established an initial scale, and newer markets like Thailand, Indonesia and the Philippines,

¹ Using the exchange rate of S\$1.00 : RM3.0799



The dynamic Ardence Aesthetics team

Mr Lim See Wah (林世华), Executive Chairman and CEO of Hyphens Pharma remarked: *“Ardence Pharma has been a strategic acquisition for the Group as it has helped to kick-start our Medical Aesthetics business with its portfolio of high quality clinically-proven aesthetic products as well as contributed to our bottom line. Now as a wholly-owned subsidiary, Ardence Pharma, and the “Ardence” brand will continue to help us drive the growth of our Medical Aesthetics business in the region. I am happy to note the progress made by our Medical Aesthetics business so far and remain confident that it will continue to develop as a sustainable growth pillar for the Group.”*

End.

Note: This media release is to be read in conjunction with the SGXNET announcement issued on the same day.

About Hyphens Pharma International Limited**(www.hyphensgroup.com)**

Hyphens Pharma International Limited and its subsidiaries (the “Group”) is Singapore’s leading specialty pharmaceutical and consumer healthcare group, driven by the belief that everyone deserves access to a better quality of life.

From its headquarters in Singapore, it maintains a direct presence in Malaysia, Vietnam, Indonesia and the Philippines, with extended reach into Thailand, Cambodia, Brunei, Bangladesh, Myanmar, Hong Kong S.A.R. and Oman. Its five key entities — Hyphens Pharma, DocMed Technology, Ocean Health, Novem, and Ardence Aesthetics, collectively advance three core business areas: Pharmaceutical and Medical Aesthetics, Proprietary Brands, and Digital Platform and E-Pharmacy.

Beyond marketing and distributing specialty pharmaceutical products across selected ASEAN markets through exclusive partnerships with global brand principals, the Group develops and commercialises proprietary dermatological and health supplement products. The Group's integrated ecosystem extends to a medical hypermart and digital pharmacy platform, enabling seamless prescription fulfilment and direct-to-patient medication delivery for healthcare providers.

Issued on behalf of	: Hyphens Pharma International Limited
For media enquiries contact	: Ms Chong Yi Sze / Ms Karina Choo / Mr Gerald Woon
Email / DID / Mobile	: yisze.chong@hyphens.com.sg / (65) 9729 6694
	karina@cogentcomms.com / (65) 6704 9280 / (65) 9107 6991
	woon@cogentcomms.com / (65) 6704 9268 / (65) 9694 8364

This media release has been reviewed by the Company’s sponsor, SAC Capital Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this media release, including the correctness of any of the statements or opinions made or reports contained in this media release.

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: (65) 6232 3210) at 1 Robinson Road, #21-01 AIA Tower, Singapore 048542.